182 related articles for article (PubMed ID: 36630591)
21. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis.
Fang F; Wang X; Li Z; Ni K; Xiong C
Mol Hum Reprod; 2021 May; 27(5):. PubMed ID: 33823008
[TBL] [Abstract][Full Text] [Related]
24. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
25. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.
Liu W; Liu C; Wang H; Xu L; Zhou J; Li S; Cheng Y; Zhou R; Zhao L
Comput Struct Biotechnol J; 2022; 20():5150-5161. PubMed ID: 36187919
[TBL] [Abstract][Full Text] [Related]
26. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
27. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of RNA modification N6-methyladenosine in human cancer.
Zhou Z; Lv J; Yu H; Han J; Yang X; Feng D; Wu Q; Yuan B; Lu Q; Yang H
Mol Cancer; 2020 Jun; 19(1):104. PubMed ID: 32513173
[TBL] [Abstract][Full Text] [Related]
30. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():765723. PubMed ID: 35003079
[TBL] [Abstract][Full Text] [Related]
31. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
32. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
33. RNA N
Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
[TBL] [Abstract][Full Text] [Related]
34. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
35. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
36. Functions of N6-methyladenosine and its role in cancer.
He L; Li H; Wu A; Peng Y; Shu G; Yin G
Mol Cancer; 2019 Dec; 18(1):176. PubMed ID: 31801551
[TBL] [Abstract][Full Text] [Related]
37. Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.
Liu WW; Wang H; Zhu XY
Biomark Res; 2022 Aug; 10(1):64. PubMed ID: 35999621
[TBL] [Abstract][Full Text] [Related]
38. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
Front Oncol; 2021; 11():642159. PubMed ID: 33816290
[TBL] [Abstract][Full Text] [Related]
39. Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology.
Zhang G; Hou J; Mei C; Wang X; Wang Y; Wang K
Biomed Pharmacother; 2023 Mar; 159():114260. PubMed ID: 36657303
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
